| Document |
Document Title |
|
WO/2024/010373A1 |
The present invention relates to antibodies that bind to an IgE-dependent histamine-releasing factor (HRF) and uses thereof. It has been confirmed that the anti-HRF antibodies according to the present invention inhibit HRF activity by bi...
|
|
WO/2024/009283A1 |
Angiotensin AT2 receptor antagonists have been clinically validated for the treatment of chronic neuropathic pain. We discovered a series of lead compounds comprising a trisubstituted heterocyclic core that show high in vitro (sub-nanomo...
|
|
WO/2024/008131A1 |
The present invention relates to new use of sivelestat, and use of sivelestat alone or in combination with a COX-2 inhibitor in preparation of a drug for treating or alleviating pain, in particular post-traumatic pain, post-operative pai...
|
|
WO/2024/008656A1 |
The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100kDa and 1000kDa and of formula (I) wherein each Rc is independently a moiety comprising a chelating agent, each Z is indepe...
|
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
|
WO/2024/007976A1 |
A compound represented by formula (I), a chiral enantiomer thereof or pharmaceutically acceptable salts thereof, and a preparation method therefor, an intermediate used for preparing the compound represented by formula (I), the chiral en...
|
|
WO/2024/002149A1 |
Provided are a recombinant type-III collagen and a method for preparing same and use thereof. The amino acid sequences of the recombinant type-III collagen are set forth in SEQ ID NOs: 1, 2, and 3.
|
|
WO/2024/005564A1 |
The present invention relates to a pharmaceutical composition comprising human pluripotent stem cell-derived mesenchymal stem cells as an active ingredient for the prevention and treatment of rotator cuff syndrome or rotator cuff tears. ...
|
|
WO/2024/002112A1 |
The present invention relates to use of a compound represented by formula (I) in resisting feline coronavirus or calicivirus infection. The compound represented by formula (I) efficiently inhibits the replication of feline coronavirus or...
|
|
WO/2024/006559A1 |
Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
|
|
WO/2024/000615A1 |
A compound capable of being used as a protein tyrosine kinase inhibitor, which can inhibit AXL, KDR and/or CSF-1R kinase. The compound can also be used for preparing a drug for treating a tumor and a related disease caused by AXL, KDR an...
|
|
WO/2024/003038A1 |
The present invention generally relates to human therapeutic effects of Bifidobacterium adolescentis, and particularly alleviating of low-grade inflammation in an elderly population.
|
|
WO/2024/006916A1 |
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
|
|
WO/2024/006820A1 |
The present disclosure provides anti-Siglec-10 antibodies and their use in treating or delaying progression of cancer, as well as compositions and kits comprising the anti-Siglec-10 antibodies.
|
|
WO/2024/001115A1 |
Disclosed are a kaurane tetracyclic diterpenoid derivative, a preparation method therefor and a medical use thereof. The present invention specifically relates to a novel derivative of a kaurane tetracyclic diterpenoid compound shown in ...
|
|
WO/2024/005526A1 |
The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhib...
|
|
WO/2024/006410A1 |
This document relates to methods and materials for treating vascular stenosis. For example, nanoparticles (e.g., poly lactic-co-glycolic acid (PLGA) nanoparticles) including one or more inhibitors of a monocyte chemoattractant protein (M...
|
|
WO/2024/004931A1 |
The purpose of the present invention is to provide an immunomodulation composition. The present invention relates to an immunomodulation composition that includes, as an active ingredient, at least one compound selected from the group th...
|
|
WO/2024/003128A1 |
The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants the...
|
|
WO/2024/003208A1 |
The invention relates to a compound of formula (I) as SIK modulators for the treatment or prophylaxis of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cel...
|
|
WO/2024/003873A1 |
The current disclosure provides an antibody polypeptide comprising a single variable domain that specifically binds a human Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α). Also provided is a polynucleic acid encoding the described ant...
|
|
WO/2024/003535A2 |
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...
|
|
WO/2024/006493A1 |
This disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salt thereof: Formula (I) in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibit...
|
|
WO/2024/005731A1 |
Invention relates to use of uridine, an endogenous molecule, in the treatment of pain in the pharmaceutical industry and health sector.
|
|
WO/2024/005506A1 |
The present invention relates to a novel compound with inhibitory activity against NADPH oxidase 2 (NOX2) and a use thereof. The compound of the present invention, an isomer thereof, or a pharmaceutically acceptable salt thereof has the ...
|
|
WO/2024/001738A1 |
Provided are a water-soluble cannabidiol microcapsule and a method for preparing same. The method comprises the following steps of: adding a galactose to an aqueous solution of whey protein isolate, regulating the pH value, reacting, and...
|
|
WO/2024/003587A1 |
The invention relates to a topical, preferably transdermal preparation and patch, which can deliver its active ingredient content into the skin with near zero-order kinetics, as well as a method for their production. The active ingredien...
|
|
WO/2024/003209A1 |
The invention relates to imidazo[4,5-c]pyridine derivatives of formula (I) as SIK modulators for the treatment or prophylaxis of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosin...
|
|
WO/2024/003533A1 |
The present invention relates to bifunctional compounds (PROTACs) of formula (I) that target the degradation of KAT2A and KAT2B, their manufacture, pharmaceutical compositions comprising the compounds and the compounds for use as medicam...
|
|
WO/2024/005197A1 |
Provided are: a solid dispersion comprising at least one compound selected from the group consisting of a hetero ring derivative represented by general formula [1], a tautomer of the hetero ring derivative, and a pharmaceutically accepta...
|
|
WO/2024/003418A1 |
Described herein is a complex of a negatively charged polysaccharide and a protein having serine protease activity. The negatively charged polypeptide can for example be heparin or non-anticoagulant heparin. The serine protease can for e...
|
|
WO/2023/246854A1 |
The present disclosure relates to a crystal of a borate derivative, a method for preparing same, and use thereof. Specifically, the present disclosure provides a crystal of a compound represented by formula I, a method for preparing same...
|
|
WO/2023/246867A1 |
The present invention provides a Nav1.8 inhibitor. Specifically, the present invention provides a compound represented by formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereo...
|
|
WO/2023/248845A1 |
The present invention provides: a novel PTX3 expression control agent that uses miRNA from fine particles to control PTX3 expression, the PTX3 expression control agent including fine particles that include miRNA that targets a gene relat...
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/248844A1 |
Provided are: an HMGB1 expression suppressor comprising a microparticle, in which the microparticle contains miRNA of which the target gene is a gene associated with the expression of HMGB1, the HMGB1 expression suppressor being a novel ...
|
|
WO/2023/246827A1 |
The present invention relates to the technical field of biological medicines, and particularly, to a micromolecular drug-oligonucleotide conjugate and use thereof. The present invention solves the problems of poor water solubility and di...
|
|
WO/2023/250036A1 |
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need ...
|
|
WO/2023/250083A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...
|
|
WO/2023/247958A1 |
The invention relates to compounds of formula (I): and their use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response, and to related compositions, methods and intermediate compounds.
|
|
WO/2023/248161A1 |
Solid state forms of Dibuprenorphine-ethyl-ether and Dibuprenorphine-ethyl-ether 2HCl are provided, as well as processes for the preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/246836A1 |
The present application relates to the technical field of biological medicines, and in particular relates to a novel five-membered heterocycle substituted styrene derivative, and a preparation method therefor and the use thereof. The sty...
|
|
WO/2023/247665A1 |
The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 rec...
|
|
WO/2023/246944A1 |
The present invention relates to a substituted 4-aminoisoindoline compound, a preparation method therefor, a pharmaceutical composition thereof, and use thereof. The compound has a structure represented by formula (I). Specifically, the ...
|
|
WO/2023/250181A1 |
Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
|
|
WO/2023/250064A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of TYK2 and in the treatment of a variety of TYK2 mediated conditions or diseases.
|
|
WO/2023/250341A2 |
The present disclosure provides human CD33 antibodies and antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of myeloid cell associated diseases.
|
|
WO/2023/249228A1 |
The present invention relates to a novel compound and use thereof for the treatment of autoimmune diseases. A pharmaceutical composition, for the treatment or prevention of an autoimmune disease, comprising the novel compound of the pres...
|
|
WO/2023/247774A1 |
The present disclosure relates to a novel treatment regimen for the treatment of autoimmune diseases and other inflammatory diseases with BTK (Bruton's tyrosine kinase) inhibitors. In particular, the present disclosure relates to a treat...
|
|
WO/2023/246858A1 |
The present disclosure relates to a pharmaceutical salt of a borate derivative, and a crystallization form and use thereof. In particular, the present disclosure provides a pharmaceutical salt of a compound represented by formula (I), an...
|
